Request Demo

Last update 11 Dec 2025

Alprazolam

Last update 11 Dec 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryAlprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway. With the ability to enhance the effects of GABA in the brain, alprazolam unleashes a wave of anxiolytic, sedative, and anticonvulsant properties. Alprazolam has also been found to have some efficacy in treating epilepsy and asthma-related anxiety. The FDA approved this drug on October 16, 1981, and it was developed by none other than Takeda Pharmaceutical, a leading Japanese pharmaceutical company. Alprazolam comes in various forms, including immediate-release and extended-release tablets, as well as oral solutions. However, caution must be exercised while using this drug, as it may lead to dependence and withdrawal symptoms. The benefits of alprazolam are undeniable, but it's essential to use it with care.

Drug Type

Small molecule drug

Synonyms

8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine, Alprazolcem, AP-1002

+ [19]

Target

DOCK5 x GABAA receptor

Action

inhibitors, agonists

Mechanism

DOCK5 inhibitors(dedicator of cytokinesis 5 inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

DyssomniasCatatoniaDepressive Disorder+ [7]

Inactive Indication

Drug abuseEpilepsies, MyoclonicMild asthma+ [1]

Originator Organization

Takeda Pharmaceutical Co., Ltd.Upjohn Pharmaceuticals Ltd.

Active Organization

Unimed Pharmaceutical, Inc.UCB Pharma SA

Teva Takeda Pharma Ltd.

+ [6]

Inactive Organization

Viatris, Inc.

Sandoz Group AGVIATRIS Pharmaceuticals Ltd.

+ [4]

License Organization

Alexza Pharmaceuticals, Inc.

Lee's Pharmaceutical Holdings Ltd.

Engage Therapeutics, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (16 Oct 1981),

Anxiety DisordersPanic Disorder

RegulationBreakthrough Therapy (China)

Structure/Sequence

Molecular FormulaC17H13ClN4

InChIKeyVREFGVBLTWBCJP-UHFFFAOYSA-N

CAS Registry28981-97-7

126

Clinical Trials associated with Alprazolam

NCT07275710

/ Not yet recruitingNot ApplicableIIT

Role of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment

To compare mean pain score between two group of participants undergoing post operative pain management after single visit root canal treatment: one group receiving NSAIDs alone and the other receiving a combination of NSAIDs and an anxiolytic medication i.e alprazolam.

Start Date01 Feb 2026

Sponsor / Collaborator-

NCT07154147

/ RecruitingPhase 4IIT

Cataract Oral vs IV Sedation Pilot RCT: A Non-inferiority Assessment of Perioperative Safety and Cognitive Recovery in Older Adults

The goal of this clinical trial is to find out if taking a pill (oral sedation) works just as well as getting medicine through a vein (IV sedation) to help older adults feel relaxed during cataract surgery. We are also studying how these two methods affect recovery, especially thinking and memory after surgery, and how satisfied people are with their care. Participants in this study will be randomly assigned to receive either oral sedation (+ IV placebo) or IV sedation (+ oral placebo) before their cataract surgery. They will complete short surveys about their thinking and recovery before and after surgery, and will be contacted by phone after surgery to check on their recovery. The results of this study will help doctors understand if a simple pill can be a safe and effective alternative to IV sedation for cataract surgery.

Start Date12 Aug 2025

Sponsor / Collaborator

The University of California, San Francisco

NCT07020988

/ RecruitingPhase 1

An Open Label, Single Dose, Randomized, Active Comparator, Quantitative Electroencephalogram Crossover Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Intravenous Midazolam and of Staccato Alprazolam Versus Nasal Diazepam in Healthy Study Participants

The purpose of this study is to estimate the difference in the time to onset of action between Staccato alprazolam and intravenous (iv) midazolam using changes in power in the combined spindle and ?1 frequency bands in the qEEG (quantitative electroencephalogram).

Start Date12 Jun 2025

Sponsor / Collaborator

UCB Biopharma SRL

100 Clinical Results associated with Alprazolam

100 Translational Medicine associated with Alprazolam

100 Patents (Medical) associated with Alprazolam

5,002

Literatures (Medical) associated with Alprazolam

01 Feb 2026·FORENSIC SCIENCE INTERNATIONAL

Drug use pattern of suspected drug-influenced drivers in Hungary (2019–2023)

Article

Author: Institóris, László ; Süvegh, Gábor ; Kereszty, Éva M ; Hidvégi, Előd ; Kovács, Katalin ; Rárosi, Ferenc ; Berkecz, Róbert ; Sija, Éva

Between 2019 and 2023, blood and urine samples of 6229 suspected impaired drivers were analysed, with a positivity rate of 91.5 %. Classical illicit drugs were detected in 4693 drivers, medicines in 850 drivers, stimulant new psychoactive substances (sNPS) in 928 drivers and synthetic cannabinoid receptor agonists (SCRAs) in 657 drivers. The consumption of cannabis, N-ethyl-norpentedron, and N-ethyl-hexedrone increased significantly over time, while the consumption of five SCRAs declined. These changes were concordant with the seizure data for the entire country. 74.2 % of drug-positive drivers were deemed impaired. Impairment was determined by fixed concentration limits in 3538 cases, multi-drug use in 507 cases, and clinical symptoms (when only one active substance with no impairment limit was present in the blood) in 217 cases. To evaluate clinical tests, the prevalence of positive and negative clinical findings was compared for amphetamine/methamphetamine, THC, MDMA, alprazolam, and clonazepam above and below their fixed concentration limits. Only alprazolam showed a significantly higher frequency of positive clinical signs above the limit. This finding suggests that the current protocol of medical examination in Hungary is inadequate for diagnosing impairment when only one active substance without a defined threshold is detected in the blood. Given that sNPS was detected in 24.1 % of drivers, the medical investigation system requires a major revision. The aim of this study was to investigate the illicit and licit drug consumption of suspected impaired drivers in Hungary and to present the disadvantages of the system currently used for diagnosing and proving impairment.

01 Dec 2025·JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Development and validation of a LC–MS/MS method for the detection of 38 benzodiazepines and 2 Z-drugs in blood

Article

Author: Liu, Xin-Ze ; Liu, Yu ; Guo, Zhen-Shuo ; Yan, Hui ; Xiang, Ping

Benzodiazepines and Z-drugs are commonly used as prescription medications to treat anxiety, epilepsy, insomnia, and alcohol withdrawal syndrome, but their use can lead to tolerance, dependence, and withdrawal reactions if taken against official guidelines. Furthermore, designer benzodiazepines, most of which lack clinical and toxicological data, have entered the illicit drug market as new psychoactive substances and are used for recreational purposes. Their abuse can cause confusion, memory loss, respiratory depression, and even death, especially when combined with other sedative-hypnotics or alcohol. Therefore, new qualitative and quantitative methods for benzodiazepines and Z-drugs are needed for use in forensic and clinical toxicology. This study explored the sample preparation and liquid-liquid extraction using 0.5 mL blood samples and 2 mL of extraction solvent for analysis of these drugs by liquid chromatography-tandem mass spectrometry and multiple reaction monitoring. The benzodiazepines were separated on a pentafluorophenylpropyl (PFPP) column using a mobile phase gradient consisting of A (water, 0.1 % formic acid, 5 % acetonitrile, and 20 mmol/L ammonium acetate) and B (acetonitrile) for 9 min. Validation steps confirmed that the method demonstrated good selectivity, sensitivity (limit of detection: 0.2 ng/mL, lower limit of quantification: 0.5 ng/mL), linearity (R² ≥ 0.99), accuracy, and precision (<20 %). Matrix effects ranged from 35 to 126 %, and recoveries ranged from 17 to 99 %, with 35 compounds having recoveries of more than 50 %. The method was successfully applied for the identification and quantification of benzodiazepines and nonbenzodiazepines in blood samples from 15 authentic poisoning cases. Ten analytes were detected: alprazolam (130.2-575.3 ng/mL), hydroxyalprazolam (2.3-37.3 ng/mL), clonazepam (11.7-773.2 ng/mL), lorazepam (63.4-166.9 ng/mL), 7-aminoclonazepam (17.4-385.3 ng/mL), oxazepam (2.6-964.1 ng/mL), diazepam (227.2 ng/mL), nordazepam(22.4 ng/mL), zolpidem (11.8-64.0 ng/mL), midazolam (70.2 ng/mL), and hydroxymidazolam (162.8 ng/mL).

01 Nov 2025·CNS DRUGS

Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders

Review

Author: Detyniecki, Kamil ; Chanteux, Hugues ; Roebling, Robert ; Strzelczyk, Adam ; Laloyaux, Cedric ; Cloyd, James C

Advances in pulmonary (PM) drug delivery through inhalation devices have enabled effective treatments for acute exacerbations of central nervous system (CNS) episodes, addressing previously unmet medical needs. While PM formulations of loxapine and levodopa are approved for agitation and off periods in Parkinson's disease (PD), respectively, there remains an unmet need for rapid-acting therapies for other acute exacerbations of neurologic disorders. In this review, the potential of PM delivery to address this gap in the management of acute CNS disorders is critically assessed, focusing on Staccato^® loxapine for agitation, Inbrija^® (levodopa) for PD, the investigational drug inhaler device Staccato^® alprazolam for epilepsy, and other investigational drug inhaler devices. PM delivery benefits from bypassing first-pass metabolism, utilizing inhalation devices to enable rapid drug delivery to the densely perfused alveolar space, arterial bloodstream, and brain. However, challenges include lung tissue sensitivity, low dose volume (compared with oral and intravenous administration), and difficulties with administration during certain acute episodes. Pharmacokinetic, efficacy, and safety data from approved or investigational PM therapies for agitation, PD, epilepsy, migraine, and insomnia present inhalation as a promising option for patients requiring acute episode management by facilitating fast absorption and onset of action and generally good tolerability. In particular, for epilepsy, on-demand medication that may be administered by patients or caregivers early at seizure onset may translate to improved patient outcomes. To enhance PM management of acute exacerbations of CNS disorders, further research and user training for optimal PM administration are required.

News (Medical) associated with Alprazolam

11 Dec 2025

·www.prnewswire.com

Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential Synergistic and complementary to Lee's Pharm's existing products pipeline, and Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Nova Pneuma Inc. ("NPI"), the Delaware incorporated and wholly owned subsidiary of Lee's Pharmaceutical Holdings Limited (0950.HK) ("Lee's Pharm" or the "Company"), announced today the assets acquisition from Alexza Pharmaceuticals, Inc. ("Alexza"). The transaction grants Lee's Pharm and NPI, the full ownership of the Staccato® One Breath Technology® ("Staccato® OBT®") platform and assets in relation to Staccato® OBT®, including intellectual property, know-how, trademarks, product pipeline, equipment, products and access to GMP facility, and Alexza's right as licensor and manufacturer of Staccato® alprazolam. This strategic move strengthens Lee's Pharm's aerosolized inhalation drug delivery capabilities, expands the Company's inhalation product pipeline, and aligns with the Company's global expansion strategy. Continue Reading GMP Facility, Fremont CA The transaction remains subject to certain closing conditions and is expected to close by the end of 2025. Proprietary And Well-Validated Staccato® One Breath Technology® The acquisition of the Staccato® OBT® platform represents a major step forward for the Company, granting full ownership of this technology platform which is a well-validated and proven platform supported by approved product, Adasuve®, and several Staccato® based late-stage development programs. This strategic move strengthens the Company's drug delivery capabilities and positions it to drive future innovation in inhalation therapeutics. Synergistic and Complementary to Lee's Pharm's Existing Products Pipeline The transaction also delivers significant synergies with the Company's existing pipeline. The Company has been advancing its clinical development of Staccato® based medicine for cancer-related breakthrough pain and started commercializing Adasuve® for acute agitation in adult schizophrenia or bipolar I disorder across Greater China. Upon completion of the acquisition, all licensing payment obligations payable thereafter by Lee's Pharm to Alexza for the development and commercialization of Staccato® based medicine and Adasuve®, will be eliminated, delivering immediate cost savings and enhancing overall deal economics. In addition, two promising CNS pipeline assets targeting Parkinson's disease and Cyclic Vomiting Syndrome (CVS), both at Phase 2 clinical stage, will be integrated into the Company's portfolio, unlocking new commercial opportunities. Acquisition of Rights as Licensor and Manufacturer of Staccato® alprazolam Under a Global Partnership With UCB Complementing these benefits, the Company acquires Alexza's rights and obligations under the existing worldwide licensing and manufacturing supply agreement with UCB, a biopharmaceutical with strong presence in epilepsy treatment. Under this agreement, UCB holds and will keep global development and commercialization rights for Staccato® alprazolam, which is currently in Phase 3 clinical trial (CinicalTrial.gov ID: NCT05077904), reinforcing the clinical maturity and commercial potential of the Staccato® OBT® platform. UCB acquired Engaged Therapeutics, Inc. for Staccato® alprazolam in June 2020 and entered into an updated license and related commercial supply agreement with Alexza.[1] Subject to achieving specified development, regulatory, and sales milestones, Lee's Pharm together with NPI may receive milestone payments totalling up to US$60.5 million, along with tiered royalties on global net sales of Staccato® alprazolam, in addition to manufacturing revenue from worldwide supply of Staccato® alprazolam. Note: [1] Source of reference: "Acquiring the Staccato® OBT® platform is a transformative step for Lee's Pharm, reinforcing our commitment to innovation in inhalation therapeutics targeting CNS and neurodegenerative disorders, and expanding our global footprint." said Dr. Benjamin Li, Founder and Director of Lee's Pharmaceutical Holdings Limited. "This transaction not only strengthens our pipeline and inhalation R&D capabilities but also creates new revenue streams through the strategic partnerships with UCB." " We are delighted to partner with UCB as it commits and advances solutions to address critical unmet needs in epileptic seizure therapy. This transaction not only delivers near-term financial benefits but also positions us for sustained growth in high-value therapeutic areas, marking a significant milestone in the Company's global expansion strategy." said Ms. Wanee Lee, Managing Director of Lee's Pharmaceutical Holdings Limited. "Under the new leadership, our team is energized to continue collaborating closely with UCB and to ensure the reliable manufacture of meaningful therapy for patients with significant unmet needs. We are equally excited about the opportunity to bring additional Staccato® based medicines to patients around the world, strengthening our shared commitment to improving lives through innovative science." said Dr. Wolfgang Schmidt, SVP Manufacturing and Operations at NPI. About Lee's Pharmaceutical Holdings Limited The Company is a research-driven and market-oriented biopharmaceutical company with more than over 30 years of operation' experience in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with around 30 international companies and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease therapeutic areas such as cardiovascular health, woman's health, paediatrics, rare diseases, oncology, dermatology and obstetrics. More information available at . About Staccato® One Breath Technology® The Staccato® One Breath Technology® is a unique and highly differentiated drug delivery technology that delivers excipient free drug as fast as intra-venous injection, but non-invasively, resulting in rapid onset of therapeutic effect. It is best positioned for treatment of acute conditions that require quick relief. The ability of the technology with the combination of different molecules to give response to unmet medical needs in an innovative manner has been well proven in large number of clinical studies with different compounds and across number of indications. The proprietary technology is well protected by large numbers of patents across different therapeutic areas. More information available at . Photo - Logo - 21% more press release views with Request a Demo

License out/inAcquisitionPhase 3

09 Dec 2025

·www.fiercepharma.com

Biocon buys out Viatris and others from biosimilar subsidiary

Biocon bought out the stakeholders in its biosimilars subsidiary, Biocon Biologics, to facilitate an integrated business. Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary.The Viatris stake is one of several that Biocon is buying back as it makes Biocon Biologics a wholly owned subsidiary. The Indian company’s strategy committee weighed multiple options, such as a merger and an IPO, before deciding this route as the “most efficient and value-accretive path forward,” Biocon explained in a Dec. 6 release.In addition to Viatris’ share, Biocon also bought out Serum Institute Life Sciences, Tata Capital and Activ Pine in a share swap that values Biocon Biologics at $5.5 billion. The company will raise additional capital through a qualified institutional placement, which will help fund the cash portion of its Viatris deal. Integrating its biosimilar subsidiary will help Biocon leverage its global commercial infrastructure, simplify its corporate structure and strengthen its position in specific therapeutic areas, including the “rapidly expanding ‘diabesity’ market,” the company said, referencing the diabetes and obesity GLP-1 drug arena.“The integration of Biocon Biologics Limited into Biocon Limited represents the next chapter in our evolution,” Biocon’s chairperson Kiran Mazumdar-Shaw commented. “Strategically, Biocon will be one of the few companies offering both biosimilars and generics at a global scale. As the only company with biosimilar insulins and generic GLP-1 peptides, Biocon is uniquely positioned to comprehensively address the needs of patients living with diabetes.”When the integration wraps up in March 2026, the new Biocon will be led by current Biocon Biologics CEO Shreehas Tambe. Current Biocon CEO Siddharth Mittal will meanwhile take on a “leadership role” within the group, the company said.Biocon currently markets 10 biosimilars and over 90 generic medicines. In 2022, the company bolstered its biosimilar portfolio with the hefty addition of Viatris’ biosimilars, the next step in a pre-existing biosimilar partnership between the two.Viatris got $3.3 billion from the cash-and-stock deal, which was inked just months after it led the first FDA-approved interchangeable biosimilar, a copy of Sanofi’s blockbuster insulin Lantus, across the regulatory finish line. At the time, Biocon expected Viatris’ biosimilars to generate $875 million in 2022 and possibly more than $1 billion in 2023. Last year, the company’s biologics subsidiary delivered on that $1 billion revenue goal after integrating Viatris’ global presence. Biosimilar moves for ViatrisBiocon’s business move is a boon for Viatris as well, as it can both monetizd its stake in Biocon and re-enter the biosimilar market in “another important step in Viatris' evolution,” CEO Scott Smith said in a company release. Biocon is taking on Viatris’ equity for $815 million in total, including $400 million in cash and $415 million in newly issued equity shares of Biocon.The stake sale will accelerate the expiration of the biosimilars non-compete restrictions previously imposed on Viatris through the 2022 deal, the company explained. With the transaction expected to close in 2026’s first quarter, the restrictions will let up immediately at the time of close for all markets outside of the U.S. and in November 2026 in the U.S. "Monetizing the value of our equity stake in Biocon Biologics and regaining access to the biosimilars market globally provides significant additional optionality as we continue to build a portfolio of generics, established brands and innovative brands that can contribute to our future growth,” Smith said.Viatris, which formed in 2020 from Mylan’s acquisition of Pfizer’s Upjohn established medicines business, markets a wide-spanning generic portfolio alongside a collection of popular branded products including, Zoloft, Xanax and Viagra. The company is currently fighting legacy parent Mylan’s battle to sell a generic version of Novo Nordisk’s lucrative semaglutide and recently launched one of the first generic threats to CSL’s iron replacement therapy Venofer.A return to the biosimilar space would be well-timed as the FDA looks to increase the availability of U.S. biosimilars with new measures to reduce clinical testing burdens, cutting down development costs and streamlining the path to market.

AcquisitionDrug ApprovalBiosimilar

19 Nov 2025

·www.einpresswire.com

JustAnswer Reveals Dramatic Shifts in Prescription Drug Concerns as Mental Health and GLP-1 Meds Dominate Queries

Over 115,000 prescription-related questions fielded on JustAnswer in 2025; weight loss drug queries surge 56% since 2023, while birth control questions dip 63% This data highlights people's desire to get immediate, trustworthy answers about drugs they’re hearing about in the news and online — whether it’s a weight-loss medication or an anxiety prescription.” — Andy Kurtzig, CEO & Founder of JustAnswer SAN FRANCISCO, CA, UNITED STATES, November 19, 2025 / EINPresswire.com / -- Consumers are increasingly turning to online medical experts to navigate complex medication choices — from trending GLP-1 medications to rising questions about anxiety and hormone treatments — according to new data from JustAnswer, the world’s largest expert platform . JustAnswer experts have fielded more than 115,000 prescription-related questions so far in 2025, but it’s the pivot in what consumers are actually asking about that reveal how dramatically patient concerns are evolving. Specifically, questions about anxiety medications, weight-loss drugs and hormone therapy have surged to dominate the conversation, while interest in categories like birth control has steadily declined. In addition, JustAnswer data showed evidence about emerging curiosity and/or discussion about medications linked to autism causes and possible treatment. “What we’re seeing is a fundamental reshaping of prescription priorities,” said JustAnswer Founder and CEO Andy Kurtzig. “People are more proactive and curious than ever — asking about new medications they’ve seen in the media, managing shortages, or trying to understand side effects and alternatives. This is one of the reasons we recently launched JustAnswer Pharmacy as an extension of our telehealthcare offering after having these conversations with our physicians.” GLP-1 Drug Questions Continue to Skyrocket Fueled by social media buzz and expanding drug availability, questions about Ozempic, Mounjaro, Wegovy, and other GLP-1 medications have risen more than 56% since 2023, hitting record highs in 2025. - Mounjaro inquiries more than doubled (+142%) from 2023 to 2025 — the fastest growth of any weight-loss drug. - Wegovy also saw a 118% increase, while Ozempic remains the most-asked-about drug overall (2,504 questions since 2023). The largest spike in this category on JustAnswer came in September 2025, coinciding with renewed public debate over shortages and widespread media coverage of celebrity use. Mental Health Medication Questions Rebound Late in 2025 Questions about Xanax, Adderall, Lorazepam, and antidepressants continue to make up one of the most active prescription categories on JustAnswer, totaling more than 13,000 questions since 2023. After a dip in 2024, question volume rebounded in late 2025, mirroring broader public conversations about stress, ADHD, and anxiety. - Xanax remains the top-searched mental health medication, accounting for 40% of all mental health–related questions (5,506 total). - Adderall inquiries declined (–31% since 2023), but 2025 saw a rebound during back-to-school and work transitions. - Mentions of Lorazepam rose notably in early 2025, coinciding with its appearance in The White Lotus TV series. Hormone Therapy Sees a Late-Year Rebound Although total hormone-related questions on JustAnswer declined slightly over the past three years (–21% from 2023 to 2025), the trend turned upward again in 2025, especially for hormone replacement therapy (HRT) – likely influenced by broad media coverage and increased advertising in the menopause telehealth space. - HRT inquiries increased 21% year-over-year in 2025, peaking in September. - Broader “Hormone Therapy” questions rose 34% since 2023, suggesting growing awareness of treatment options beyond testosterone, which still accounts for 72% of all hormone-related inquiries. Emerging Curiosity Around Medications Linked to Possible Autism Causes and Treatment While not a prescription drug, one OTC medication did see a meaningful increase within the data. Tylenol questions rose significantly in late 2025, peaking in September, aligning with the public debate sparked by comments from Donald Trump and Robert F. Kennedy Jr. claiming a link between acetaminophen and autism. On the other end of the autism discussion, another drug saw a singular spike this fall: Leucovorin, a medication sometimes discussed in relation to autism, received 1,200% more questions YOY in 2025, peaking in October. This marks the sharpest growth in any prescription drug category on the platform and likely reflects new awareness generated by the MAHA movement, online communities and media discussions around emerging off-label uses for treatment of autism in children. Category in Decline: Birth Control On the other hand, questions about birth control, Mifepristone, and Misoprostol have declined on JustAnswer by 63% since 2023, signaling reduced public engagement with these medications. “Overall, this data highlights the desire for people to get immediate, trustworthy answers about new drugs they’re hearing about in the news and online — whether it’s a weight-loss medication or an anxiety prescription — and platforms like ours give them that access in real time,” said Kurtzig. “And now with JustAnswer Pharmacy, they also have a convenient, affordable way to acquire these and many prescription medications they need under medical supervision.” About JustAnswer JustAnswer is the world’s largest expert platform that connects people with live doctors, lawyers, vets, mechanics, and other verified professionals for real-time, online help. Featuring more than 20,000 experts across 150 categories, JustAnswer has helped millions of customers across 196 countries since 2003. Aimee Grove Smitten Communications aimee@smittencomm.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Alprazolam

External Link

KEGG	Wiki	ATC	Drug Bank
D00225	Alprazolam	N05BA12	DB00404

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dyssomnias	South Korea	Unimed Pharmaceutical, Inc.	13 Mar 2025
Catatonia	Japan	Teva Takeda Pharma Ltd.	15 Feb 1984
Depressive Disorder	Japan	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Depressive Disorder	Japan	Teva Takeda Pharma Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	Japan	Teva Takeda Pharma Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	Japan	T’s Pharma Co., Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	Japan	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Anxiety Disorders	United States	Upjohn US 2 LLC	16 Oct 1981
Panic Disorder	United States	Upjohn US 2 LLC	16 Oct 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsy	Phase 3	Belgium	UCB SA	30 Jan 2022
Epilepsy, Absence	Phase 3	United States	UCB Trading (Shanghai) Co., Ltd.	07 Dec 2021
Epilepsy, Absence	Phase 3	United States	UCB Pharma SA	07 Dec 2021
Epilepsy, Absence	Phase 3	United States	Alexza Pharmaceuticals, Inc.	07 Dec 2021
Epilepsy, Absence	Phase 3	Japan	UCB Pharma SA	07 Dec 2021
Epilepsy, Absence	Phase 3	Japan	Alexza Pharmaceuticals, Inc.	07 Dec 2021
Epilepsy, Absence	Phase 3	Japan	UCB Trading (Shanghai) Co., Ltd.	07 Dec 2021
Epilepsy, Absence	Phase 3	Australia	UCB Pharma SA	07 Dec 2021
Epilepsy, Absence	Phase 3	Australia	Alexza Pharmaceuticals, Inc.	07 Dec 2021
Epilepsy, Absence	Phase 3	Australia	UCB Trading (Shanghai) Co., Ltd.	07 Dec 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05626439 (P9-9.009, AAN2025)	Phase 1	Seizures	21	Staccato Alprazolam 2mg	exonxhzjwf(jscojcltys) = pjbiflwbas ojjqsxcijt (zhuwexpcgr )	Positive	07 Apr 2025
				Oral Alprazolam 2mg	exonxhzjwf(jscojcltys) = lpztzxifet ojjqsxcijt (zhuwexpcgr )
NCT04782388 (UP0101, AAN2024)	Phase 1	-	-	Staccato Alprazolam 2 mg	leqqvxigqn(tutsqnvfyy) = AUC0-t showed a similar trend to AUCinf ovxzshxybh (nkbnwazabg ) View more	Positive	09 Apr 2024
				Staccato Placebo
NCT04970342 (PDID, CTgov)	Phase 1	-	13	Placebo (Lactose) Capsule+CBD+THC ("Sober" or Double Placebo)	nvnihbpewj(bzalqsedna) = barrobajrg efrijoexox (iqzdvzyiwg, 5.737) View more	-	25 Jul 2023
				CBD+0.75 mg Alprazolam Capsule+THC (Active Alprazolam (Xanax), Placebo Cannabis)	nvnihbpewj(bzalqsedna) = rjxvypesbm efrijoexox (iqzdvzyiwg, 6.434) View more
NCT03478982 (ENGAGE-E-001, Pubmed)	Phase 2	Epilepsy	116	Staccato® alprazolam 1.0 mg	rduxdxslhe(lerwbvyuth) = cesfzbaqfn gfrqpdpgid (itelcftbed )	-	21 Oct 2022
				Staccato® alprazolam 2.0 mg	rduxdxslhe(lerwbvyuth) = oloquidixg gfrqpdpgid (itelcftbed )
NCT02351115 (CTgov)	Phase 2	Epilepsy	5	placebo (Inhaled Placebo)	dapsuwskub(exbnomkjki) = jkyrifpcal ntldvrmznl (epnbritwml, wzlvhffimn - lqzzmjejna) View more	-	10 Aug 2021
				Staccato+Alprazolam (Staccato Alprazolam, 0.5 mg)	dapsuwskub(exbnomkjki) = mmpzosgory ntldvrmznl (epnbritwml, urhqtmwxld - fvcxsbjduf) View more
NCT03478982 (StATES \| P1.5-023 \| ENGAGE-E-001, CTgov)	Phase 2	Seizures \| Epilepsy \| Epilepsies, Myoclonic	156	Staccato Alprazolam (STAP-001) (Open-label: Staccato Alprazolam (STAP-001) 1.0 Milligram (mg))	kxfowfhuhc = tyirervwjz ngvxlvslnq (oxgifmayza, cbhegoallo - pstduuvkui) View more	-	03 Feb 2021
				placebo+alprazolam (Double-blind: Placebo)	kxfowfhuhc = wopntkaddr ngvxlvslnq (oxgifmayza, xnzqaqqefz - xzasgzdtte) View more
NCT03297944 (CTgov)	Phase 4	Psychomotor Disorders	15	Placebo (PLC/PLC)+ZOL+PLC+Alprazolam+Zolpidem+ALC	mramxpjbcf(klkevmxlml) = vpqfgvqioe fsyshkifna (gpneytubss, qzekrscdek - rcsvuheoqv) View more	-	29 Jan 2020
NCT00603980 (CTgov)	Phase 1	Drug abuse	31	placebo (Placebo)	vumwuqdqcz(aryclnvwef) = frryuluiam hvpdvimwzf (xczotnflcu, 0.349) View more	-	02 Jan 2020
				Alprazolam (Oral Alprazolam 1 mg)	vumwuqdqcz(aryclnvwef) = kpnhzlqumd hvpdvimwzf (xczotnflcu, 0.349) View more
NCT00662259 (GAD, CTgov)	Phase 4	Generalized anxiety disorder	32	Xanax (Alprazolam)	ewqlzgsxiw(dsgrystmov) = mebwthtgam bmogpvoetq (gpbwyasxin, .1529) View more	-	25 Jul 2019
				Placebo (Placebo)	ewqlzgsxiw(dsgrystmov) = gnytvqklgm bmogpvoetq (gpbwyasxin, .1123) View more
NCT03478982 (P1.5-023, AAN2019)	Phase 2	Epilepsy	8	Staccato Alprazolam 1 mg	hikctiwrxc(dkbkdswfuq) = no adverse events were serious or severe zlarzzahxb (hakstzcgpo )	Positive	09 Apr 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Alprazolam

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation